Details for New Drug Application (NDA): 209090
✉ Email this page to a colleague
NDA 209090 describes XYZAL ALLERGY 24HR, which is a drug marketed by Chattem Sanofi and is included in two NDAs. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the XYZAL ALLERGY 24HR profile page.
The generic ingredient in XYZAL ALLERGY 24HR is levocetirizine dihydrochloride. There are thirteen drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the levocetirizine dihydrochloride profile page.
The generic ingredient in XYZAL ALLERGY 24HR is levocetirizine dihydrochloride. There are thirteen drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the levocetirizine dihydrochloride profile page.
Summary for 209090
| Tradename: | XYZAL ALLERGY 24HR |
| Applicant: | Chattem Sanofi |
| Ingredient: | levocetirizine dihydrochloride |
| Patents: | 1 |
Pharmacology for NDA: 209090
| Mechanism of Action | Histamine H1 Receptor Antagonists |
Suppliers and Packaging for NDA: 209090
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| XYZAL ALLERGY 24HR | levocetirizine dihydrochloride | SOLUTION;ORAL | 209090 | NDA | Chattem, Inc. | 41167-3530 | 41167-3530-1 | 1 BOTTLE in 1 CARTON (41167-3530-1) / 148 mL in 1 BOTTLE |
| XYZAL ALLERGY 24HR | levocetirizine dihydrochloride | SOLUTION;ORAL | 209090 | NDA | Chattem, Inc. | 41167-3533 | 41167-3533-0 | 1 BOTTLE in 1 CARTON (41167-3533-0) / 148 mL in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | OTC | Dosage: | SOLUTION;ORAL | Strength | 2.5MG/5ML | ||||
| Approval Date: | Jan 31, 2017 | TE: | RLD: | Yes | |||||
| Patent: | 8,633,194 | Patent Expiration: | Oct 16, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
